Follitropin alfa/lutropin alfa

Drug Profile

Follitropin alfa/lutropin alfa

Alternative Names: Lutropin alfa/follitropin alfa; Pergoveris; Recombinant human follicle stimulating hormone/luteinising hormone; rh-FSH/LH

Latest Information Update: 18 May 2017

Price : $50

At a glance

  • Originator Serono Europe
  • Developer Merck Serono Co Ltd; Serono Europe
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Luteinising hormone stimulants; Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Female infertility

Most Recent Events

  • 10 May 2017 The European Commission approves a liquid version of pre-filled Pergoveris™ Pen for the treatment of Female fertility in European Union
  • 01 Jan 2015 Merck initiates a phase I bioequivalence trial for Healthy volunteers in Germany (NCT02317809)
  • 11 Dec 2014 Merck plans a phase I bioequivalence trial for Healthy volunteers in Germany (NCT02317809)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top